Melanoma & Skin Cancer

Janice Mehnert, MD, discusses the rationale for adding IL-6 inhibition to an ICI backbone and data with sarilumab plus ICIs in advanced melanoma.

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

Among patients with advanced melanoma and the target HLA type—representing 80% of the study population—treatment with iSCIB1+ yielded an ORR of 69%.

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen.

Piotr Rutkowski, MD, discusses a trial evaluating the nivolumab biosimilar JPB898 plus ipilimumab in stage III or metastatic stage IV melanoma.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

The combination of sarilumab, ipilimumab, nivolumab, and relatlimab displayed activity in patients with stage III or IV melanoma.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Janice M. Mehnert, MD, discusses the efficacy and safety profile of sarilumab plus ipilimumab, nivolumab, and relatimab in unresectable melanoma.

Douglas B. Johnson, MD, MSCI, discusses clinical questions, unmet needs, and exciting therapeutic developments with immuno-oncology in melanoma.

Theresa Medina, MD, discusses the long-term efficacy and safety of lifileucel TIL therapy in advanced melanoma.

Ahmad A. Tarhini, MD, PhD, discusses findings from the ECOG-ACRIN EA6194 trial of pembrolizumab plus vidutolimod in resectable melanoma.

Phase 2 findings from NAUTILUS supported the potential combinatorial activity of binimetinib plus bocodepsin in NRAS-mutant melanoma.

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Encorafenib plus binimetinib and nivolumab improved PFS in BRAF V600–mutant melanoma with symptomatic brain metastases.

On June 2, 2025, a group of oncologists gathered for an in-person workshop at the 2025 Annual Meeting of the American Society of Clinical Oncology to discuss advances in cutaneous squamous cell carcinoma (cSCC) treatment. Moderated by Soo Park, MD, the session focused on adjuvant, high-risk neoadjuvant and metastatic treatment, including the use of immune checkpoint inhibitors (ICIs). Faculty reviewed clinical trial data, shared real-world experiences, and debated evolving treatment strategies.

Douglas B. Johnson, MD, MSCI, discusses the importance of Cancer Immunotherapy Awareness Month and the utility of immunotherapy across tumor types.

Douglas B. Johnson, MD, MSCI, highlighted avenues for improving immunotherapy use in melanoma during Cancer Immunotherapy Awareness Month.

Ahmad Tarhini, MD, PhD, discusses key findings from the EA6194 trial and how these data support the continued investigation of vidutolimod in melanoma.

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.

The FDA has lifted the partial clinical hold on a phase 3 study assessing IFx-2.0 in advanced Merkel cell carcinoma.

Jason Luke, MD, discusses IMA203 vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.

RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.

Dostarlimab plus cobolimab bested dostarlimab monotherapy in terms of MPR and RFS in patients with high-risk resectable melanoma.